Norgine寻求欧盟批准Eflornithine, 以防止神经病患者复发。 Norgine seeks EU approval for eflornithine to prevent relapse in neuroblastoma patients.

Norgine已经向欧洲药品局提出申请,要求接受evellnithine,这是一项口服疗法,以减少高危神经肌肉瘤患者复发的风险。 Norgine has submitted an application to the European Medicines Agency for eflornithine, an oral therapy to reduce the risk of relapse in high-risk neuroblastoma patients. 这是在美国批准以及澳大利亚、瑞士和联合王国提交材料之后提出的。 This follows approvals in the US and submissions in Australia, Switzerland, and the UK. 治疗旨在向接受过先前治疗的成人和儿童扩大治疗范围。 The therapy aims to extend remission in both adults and children who have received prior treatments. Norgine和美国WorldMeds有一份许可证协议,以便在欧洲、澳大利亚和新西兰对elolntihine进行登记和商业化。 Norgine and US WorldMeds have a licensing agreement to register and commercialize eflornithine in Europe, Australia, and New Zealand.